GlassScriptPhysician profile
Agna Elizabeth Bailey
NPI 1598762825
$3,225.18
in general payments reported to CMS, 2019-2025
35 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $1,072 · 2022: $21.78 · 2023: $375 · 2024: $440 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,398.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.67 | 2019-2025 | Jardiance |
| Allergan, INC. | $261.39 | 2019-2020 | |
| Novo Nordisk INC | $252.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $245.82 | 2019-2025 | |
| Lilly USA, LLC | $179.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $179.24 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $126.50 | 2019-2024 | |
| Motiva USA, LLC | $120.08 | 2025 | |
| Abbvie INC. | $104.19 | 2023-2024 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.25 | 2019-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $77.54 | 2020-2023 | Rexulti |
| Glaxosmithkline, LLC. | $73.30 | 2019-2024 | Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $58.32 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $57.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $54.05 | 2023-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $47.42 | 2020-2023 | Dificid |
| Upsher-Smith Laboratories LLC | $40.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.77 | 2019-2020 | |
| Amarin Pharma, INC. | $31.90 | 2020 | |
| Biogen, INC. | $29.73 | 2024 | Skyclarys |
| Shire North American Group INC | $29.72 | 2019 | |
| Phathom Pharmaceuticals, INC. | $28.90 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.34 | 2023 | |
| Mallinckrodt Hospital Products INC. | $23.81 | 2025 | Terlivaz |
| Insulet Corporation | $23.32 | 2019 | |
| Ibsa Pharma INC. | $21.45 | 2025 | Tirosint, Flector, Licart |
| Eisai INC. | $16.59 | 2020 | |
| Avvisto Therapeutics, LLC | $16.10 | 2025 | Cycloset |
| Si-Bone, INC. | $15.84 | 2019 | |
| Mdd US Operations, LLC | $14.70 | 2019 | |
| Dexcom, INC. | $13.42 | 2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $12.86 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.51 | 2019 | |
| Tanabe Pharma America, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agna Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.